Viridian Therapeutics stock weighs Lumvoa uptake against losses

Published on 09/30/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RBC lifted its Viridian target from USD 36.00 to USD 38.00 on September 22, 2026. Q2 EPS came in at minus USD 1.05.

VRDN, US92769V1044, Illustration mit AI erstellt.

Viridian Therapeutics (ISIN US92769V1044) is weighing Lumvoa's early commercial traction against a Q2 2026 loss of USD 1.05 per share. Bitget carried a Reuters report dated September 22, 2026 that RBC raised its price target from USD 36.00 to USD 38.00 while maintaining an outperform rating with speculative risk.

Lumvoa gains early traction

Simply Wall St reported on September 24, 2026 that RBC viewed Lumvoa's commercial rollout as stronger than anticipated. The drug targets thyroid eye disease, and the report said half of six surveyed physicians had written at least one prescription since the June 26 launch.

The same assessment identified access as the near-term counterweight. A permanent J-code and formulary progress at academic centers could influence how quickly early demand converts into reimbursed treatment volume.

Losses keep the story speculative

Viridian's Q2 2026 revenue was USD 0.28 million, above the USD 0.06 million consensus estimate, while EPS of minus USD 1.05 missed the USD 1.03 loss estimate by USD 0.02. MarketBeat reported these figures after the August 6, 2026 earnings release and cited a negative net margin of 505.86 percent.

The contrast is material for investors: commercial demand is becoming measurable, but the earnings profile still reflects a clinical-stage biotechnology business. Viridian also held USD 164.99 million in cash at June 30, 2026, while operating cash flow for Q2 was negative USD 105.32 million.

Target sits above the Nasdaq quote

VRDN was last at USD 20.00 on Nasdaq on September 29, 2026 at 4:00 p.m. ET. The stock's 52-week range was USD 13.18 to USD 34.29, and its market capitalization was USD 2.3 billion on that date.

Investing.com lists November 16, 2026 as the next earnings date. That report should show whether Lumvoa's launch translates into a larger commercial revenue base while the company continues funding its pipeline.